董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
H. Lawrence Culp, Jr. Chairman of the Board 61 45.49万美元 39.87 2025-07-23
Peter J. Arduini President, Chief Executive Officer and Director 59 1948.79万美元 6.38 2025-07-23
Risa Lavizzo Mourey Independent Lead Director 70 37.99万美元 0.46 2025-07-23
Anne T. Madden Independent Director 60 32.49万美元 未持股 2025-07-23
Tomislav Mihaljevic Independent Director 61 32.49万美元 未持股 2025-07-23
Catherine Lesjak Independent Director 66 34.99万美元 0.36 2025-07-23
Phoebe L. Yang Independent Director 56 32.49万美元 未持股 2025-07-23
Rodney F. Hochman Independent Director 69 32.49万美元 未持股 2025-07-23
William J. Stromberg Independent Director 65 34.49万美元 未持股 2025-07-23

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Kevin M. O'Neill President and CEO, Pharmaceutical Diagnostics 57 未披露 未持股 2025-07-23
Roland Rott President and CEO, Imaging 54 392.50万美元 1.14 2025-07-23
Thomas J. Westrick President and CEO, Patient Care Solutions 57 未披露 未持股 2025-07-23
Philip Rackliffe President and CEO, Advanced Visualization Solutions 51 未披露 未持股 2025-07-23
Peter J. Arduini President, Chief Executive Officer and Director 59 1948.79万美元 6.38 2025-07-23
James K. Saccaro Vice President and Chief Financial Officer 52 567.09万美元 1.72 2025-07-23
Taha Kass Hout Chief Science and Technology Officer 53 571.90万美元 3.52 2025-07-23
Kenneth Stacherski Chief Global Supply Chain and Service Officer 54 未披露 未持股 2025-07-23
George A. Newcomb -- Chief Accounting Officer -- 未披露 未持股 2025-07-23
Adam Y. Holton Chief People Officer 54 未披露 未持股 2025-07-23
Frank R. Jimenez General Counsel and Corporate Secretary 60 540.35万美元 4.11 2025-07-23

董事简历

中英对照 |  中文 |  英文
H. Lawrence Culp, Jr.

H. Lawrence Culp, Jr.,自2018年9月起担任GE的董事长兼首席执行官,领导GE转型成为一家更专注、更简单、更强大的高科技工业公司。在他的领导下,到2023年,通用电气的总债务削减总额超过1000亿美元。他是通用电气组建三家行业领先的全球上市公司计划的主要策划者,并曾担任通用医疗科技公司(GE Healthcare Technologies Inc.)董事长。自2023年1月成功分拆以来,担任董事会成员。他还自2022年6月起担任GE Aerospace的首席执行官,并将在2024年4月GE的能源业务组合分拆后继续领导这家以航空为重点的公司走向未来。在加入GE之前,他在Danaher Corporation (NYSE: DHR)担任了25年的各种职务,包括集团执行官和公司官,负责公司的环境和电子测试和测量平台,同时还担任Fluke和Fluke Networks的总裁;执行副总裁;首席运营官;2000年至2014年担任总裁兼首席执行官。在他任职期间,丹纳赫的收入和市值都增长了五倍。在年度机构投资者调查中,投资者和分析师一直将他评为最佳首席执行官之一,《哈佛商业评论》将他评为全球前50位首席执行官之一。


H. Lawrence Culp, Jr.,is the Chairman and Chief Executive Officer of General Electric Company, operating as GE Aerospace. Mr. Culp joined the GE Board of Directors in April 2018 and was appointed Chief Executive Officer of GE in October 2018. In June 2022, he assumed additional duty as Chief Executive Officer of GE Aerospace and became Chairman and Chief Executive Officer of GE Aerospace when it launched as a public company in April 2024. He has also served as the non-executive Chairman of Ge Healthcare Technologies Inc. Board since the Spin-Off. As Chairman and Chief Executive Officer of GE, Mr. Culp led the industrial technology company's multi-year financial and operational transformation. Under his leadership, GE further focused the company's portfolio and simultaneously improved operations across its businesses by implementing and adopting lean with a relentless focus on safety, quality, delivery, and cost—in that order—to better serve customers. These efforts built a strong foundation for the successful creation of three independent, investment-grade public companies GE HealthCare, GE Vernova, and GE Aerospace. Each company is an industry leader with extensive global installed bases and a strong services orientation. Prior to joining GE, Mr. Culp spent 25 years at Danaher Corporation, including serving as President and Chief Executive Officer from 2001 to 2014. Mr. Culp joined Danaher in 1990 at Veeder-Root, becoming President in 1993. He was appointed Group Executive and Corporate Officer in 1995, with responsibility for Danaher's Environmental and Electronic Test and Measurement platforms while also serving as President of Fluke and Fluke Networks. He was named Executive Vice President in 1999, Chief Operating Officer in 2000, and President and Chief Executive Officer in 2001. Mr. Culp is a graduate of Harvard Business School and served as a Senior Lecturer from 2015 to 2018.
H. Lawrence Culp, Jr.,自2018年9月起担任GE的董事长兼首席执行官,领导GE转型成为一家更专注、更简单、更强大的高科技工业公司。在他的领导下,到2023年,通用电气的总债务削减总额超过1000亿美元。他是通用电气组建三家行业领先的全球上市公司计划的主要策划者,并曾担任通用医疗科技公司(GE Healthcare Technologies Inc.)董事长。自2023年1月成功分拆以来,担任董事会成员。他还自2022年6月起担任GE Aerospace的首席执行官,并将在2024年4月GE的能源业务组合分拆后继续领导这家以航空为重点的公司走向未来。在加入GE之前,他在Danaher Corporation (NYSE: DHR)担任了25年的各种职务,包括集团执行官和公司官,负责公司的环境和电子测试和测量平台,同时还担任Fluke和Fluke Networks的总裁;执行副总裁;首席运营官;2000年至2014年担任总裁兼首席执行官。在他任职期间,丹纳赫的收入和市值都增长了五倍。在年度机构投资者调查中,投资者和分析师一直将他评为最佳首席执行官之一,《哈佛商业评论》将他评为全球前50位首席执行官之一。
H. Lawrence Culp, Jr.,is the Chairman and Chief Executive Officer of General Electric Company, operating as GE Aerospace. Mr. Culp joined the GE Board of Directors in April 2018 and was appointed Chief Executive Officer of GE in October 2018. In June 2022, he assumed additional duty as Chief Executive Officer of GE Aerospace and became Chairman and Chief Executive Officer of GE Aerospace when it launched as a public company in April 2024. He has also served as the non-executive Chairman of Ge Healthcare Technologies Inc. Board since the Spin-Off. As Chairman and Chief Executive Officer of GE, Mr. Culp led the industrial technology company's multi-year financial and operational transformation. Under his leadership, GE further focused the company's portfolio and simultaneously improved operations across its businesses by implementing and adopting lean with a relentless focus on safety, quality, delivery, and cost—in that order—to better serve customers. These efforts built a strong foundation for the successful creation of three independent, investment-grade public companies GE HealthCare, GE Vernova, and GE Aerospace. Each company is an industry leader with extensive global installed bases and a strong services orientation. Prior to joining GE, Mr. Culp spent 25 years at Danaher Corporation, including serving as President and Chief Executive Officer from 2001 to 2014. Mr. Culp joined Danaher in 1990 at Veeder-Root, becoming President in 1993. He was appointed Group Executive and Corporate Officer in 1995, with responsibility for Danaher's Environmental and Electronic Test and Measurement platforms while also serving as President of Fluke and Fluke Networks. He was named Executive Vice President in 1999, Chief Operating Officer in 2000, and President and Chief Executive Officer in 2001. Mr. Culp is a graduate of Harvard Business School and served as a Senior Lecturer from 2015 to 2018.
Peter J. Arduini

Peter J. Arduini,Integra的总裁、首席执行官及董事。他于2010年11月加入Integra担任总裁兼首席营运官,于2012年1月被任命为首席执行官兼董事。在加入Integra之前,他曾于2005年加入Baxter Healthcare并担任企业副总裁及药物输注部总裁。他负责Baxter一个市值48亿美元的全球部门。在加入Baxter之前,他受雇于 General Electric Healthcare,担任了一系列国内外业务的管理职务,最近担任GE Healthcare公司的全球总经理,负责计算机轴向断层扫描(CT)和功能成像业务。在加入 General Electric Healthcare之前,他在宝洁(Procter and Gamble)工作了4年,从事销售和营销工作。他在先进医疗技术协会(ADVAMED)和国家意大利裔美国基金会(the National Italian American Foundation)的董事会任职。他持有Susquehanna University 的营销学学士学位和西北大学凯洛格管理学院( Northwestern University's Kellogg School of Management)的管理学硕士学位。


Peter J. Arduini,was appointed as President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE's healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences ("Integra"), a global medical technology company, from January 2012 to December 2021. During his tenure as Integra's Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE's healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales.
Peter J. Arduini,Integra的总裁、首席执行官及董事。他于2010年11月加入Integra担任总裁兼首席营运官,于2012年1月被任命为首席执行官兼董事。在加入Integra之前,他曾于2005年加入Baxter Healthcare并担任企业副总裁及药物输注部总裁。他负责Baxter一个市值48亿美元的全球部门。在加入Baxter之前,他受雇于 General Electric Healthcare,担任了一系列国内外业务的管理职务,最近担任GE Healthcare公司的全球总经理,负责计算机轴向断层扫描(CT)和功能成像业务。在加入 General Electric Healthcare之前,他在宝洁(Procter and Gamble)工作了4年,从事销售和营销工作。他在先进医疗技术协会(ADVAMED)和国家意大利裔美国基金会(the National Italian American Foundation)的董事会任职。他持有Susquehanna University 的营销学学士学位和西北大学凯洛格管理学院( Northwestern University's Kellogg School of Management)的管理学硕士学位。
Peter J. Arduini,was appointed as President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE's healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences ("Integra"), a global medical technology company, from January 2012 to December 2021. During his tenure as Integra's Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE's healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales.
Risa Lavizzo Mourey

Risa Lavizzo Mourey, 1986年至2021年担任University of Pennsylvania教授,2018年至2021年担任Robert Wood Johnson Foundation卫生公平和卫生政策教授。2003年至2017年,Lavizzo-Mourey博士担任Robert Wood Johnson Foundation的首席执行官,在那里她率先采取行动,扭转儿童肥胖流行病,创建负担得起的包容性医疗保健系统,并解决与不利健康影响相关的社会因素。从1985年到1998年,她还拥有丰富的政府工作经验,担任各种职务,包括担任White House Health Care Reform Task Force的联合主席,以及担任the President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry的咨询委员会成员。Lavizzo-Mourey博士自2021年起担任Better Therapeutics, Inc.(Nasdaq:BTTX)的董事会成员,在那里她担任薪酬委员会成员;自2018年起担任英特尔(NYSE:INTC)的董事会成员,在那里她担任公司治理和提名委员会主席,审计和财务委员会和薪酬委员会成员,自2020年起担任Merck(NYSE:MRK)董事会成员,担任薪酬与管理发展委员会和研究委员会成员;自2017年以来,她是General Electric(NYSE:GE)的董事会成员,在那里她是治理和公共事务委员会成员。她拥有State University of New York, Stony Brook的学士学位、哈佛大学的医学博士学位和University of Pennsylvania的工商管理硕士学位。


Risa Lavizzo Mourey,has served as Lead Director of Board since the Spin-Off. Dr. Lavizzo-Mourey served as the Robert Wood Johnson Foundation Professor of Health Equity and Health Policy from January 2018 to January 2021. From 2003 to 2017, Dr. Lavizzo-Mourey was the Chief Executive Officer of the Robert Wood Johnson Foundation, where she spearheaded initiatives to reverse the childhood obesity epidemic, create an affordable and inclusive healthcare system, and address social factors associated with adverse health impacts. Dr. Lavizzo-Mourey was a professor at the University of Pennsylvania from 1986 until 2003 where she served as Chief of Geriatric Medicine and Director of the Institute of Aging. She also has extensive government experience in a wide range of roles from 1985 to 1998, including as a Co-Chair of the White House Health Care Reform Task Force and as an Advisory Committee Member on the President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry.
Risa Lavizzo Mourey, 1986年至2021年担任University of Pennsylvania教授,2018年至2021年担任Robert Wood Johnson Foundation卫生公平和卫生政策教授。2003年至2017年,Lavizzo-Mourey博士担任Robert Wood Johnson Foundation的首席执行官,在那里她率先采取行动,扭转儿童肥胖流行病,创建负担得起的包容性医疗保健系统,并解决与不利健康影响相关的社会因素。从1985年到1998年,她还拥有丰富的政府工作经验,担任各种职务,包括担任White House Health Care Reform Task Force的联合主席,以及担任the President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry的咨询委员会成员。Lavizzo-Mourey博士自2021年起担任Better Therapeutics, Inc.(Nasdaq:BTTX)的董事会成员,在那里她担任薪酬委员会成员;自2018年起担任英特尔(NYSE:INTC)的董事会成员,在那里她担任公司治理和提名委员会主席,审计和财务委员会和薪酬委员会成员,自2020年起担任Merck(NYSE:MRK)董事会成员,担任薪酬与管理发展委员会和研究委员会成员;自2017年以来,她是General Electric(NYSE:GE)的董事会成员,在那里她是治理和公共事务委员会成员。她拥有State University of New York, Stony Brook的学士学位、哈佛大学的医学博士学位和University of Pennsylvania的工商管理硕士学位。
Risa Lavizzo Mourey,has served as Lead Director of Board since the Spin-Off. Dr. Lavizzo-Mourey served as the Robert Wood Johnson Foundation Professor of Health Equity and Health Policy from January 2018 to January 2021. From 2003 to 2017, Dr. Lavizzo-Mourey was the Chief Executive Officer of the Robert Wood Johnson Foundation, where she spearheaded initiatives to reverse the childhood obesity epidemic, create an affordable and inclusive healthcare system, and address social factors associated with adverse health impacts. Dr. Lavizzo-Mourey was a professor at the University of Pennsylvania from 1986 until 2003 where she served as Chief of Geriatric Medicine and Director of the Institute of Aging. She also has extensive government experience in a wide range of roles from 1985 to 1998, including as a Co-Chair of the White House Health Care Reform Task Force and as an Advisory Committee Member on the President's Advisory Commission on Consumer Protection and Quality in the Health Care Industry.
Anne T. Madden

Anne T. Madden将因此次分拆而被任命为Ge Healthcare Technologies Inc.的董事会成员。自2017年10月起,Madden女士担任Honeywell International Inc.(“Honeywell”)高级副总裁兼总法律顾问。在此之前,Madden女士在Honeywell担任了16年的企业发展副总裁兼全球并购主管。在她任职期间,Honeywell进行了约100项收购,约合150亿美元的收入,并剥离了约70项业务,约合90亿美元的非核心收入。Madden女士于1996年加入Honeywell的前身AlliedSignal,担任面粉产品总法律顾问,并于当年晚些时候成为副总裁兼特种化学品总法律顾问,然后成为副总裁兼性能材料和技术副总法律顾问。在她职业生涯的早期,Madden曾在Shearman & Sterling和毕马威工作。她是Honeywell子公司Quantinuum的董事会成员。Madden女士拥有布朗大学英美文学学士学位、纽约大学斯特恩商学院会计学硕士学位和金融硕士学位,以及福特汉姆大学法学院法学博士学位。


Anne T. Madden,has served as a member of Board since the Spin-Off. Since October 2017, Ms. Madden has served as Senior Vice President and General Counsel at Honeywell International Inc. ("Honeywell"), a diversified technology and manufacturing company, where she also served as Corporate Secretary from January 2018 to September 2019. Prior to that, Ms. Madden was Vice President, Corporate Development and Global Head of M&A at Honeywell for sixteen years. During her tenure, Honeywell made approximately 100 acquisitions representing approximately $15 billion in revenues and divested approximately 70 businesses representing close to $9 billion of non-core revenues. Ms. Madden joined AlliedSignal, Honeywell's predecessor, in 1996 as General Counsel of Fluorine Products and, later that year, became Vice President and General Counsel of Specialty Chemicals and then Vice President and Deputy General Counsel of Performance Materials and Technologies. Earlier in her career, Ms. Madden worked at Shearman & Sterling and KPMG.
Anne T. Madden将因此次分拆而被任命为Ge Healthcare Technologies Inc.的董事会成员。自2017年10月起,Madden女士担任Honeywell International Inc.(“Honeywell”)高级副总裁兼总法律顾问。在此之前,Madden女士在Honeywell担任了16年的企业发展副总裁兼全球并购主管。在她任职期间,Honeywell进行了约100项收购,约合150亿美元的收入,并剥离了约70项业务,约合90亿美元的非核心收入。Madden女士于1996年加入Honeywell的前身AlliedSignal,担任面粉产品总法律顾问,并于当年晚些时候成为副总裁兼特种化学品总法律顾问,然后成为副总裁兼性能材料和技术副总法律顾问。在她职业生涯的早期,Madden曾在Shearman & Sterling和毕马威工作。她是Honeywell子公司Quantinuum的董事会成员。Madden女士拥有布朗大学英美文学学士学位、纽约大学斯特恩商学院会计学硕士学位和金融硕士学位,以及福特汉姆大学法学院法学博士学位。
Anne T. Madden,has served as a member of Board since the Spin-Off. Since October 2017, Ms. Madden has served as Senior Vice President and General Counsel at Honeywell International Inc. ("Honeywell"), a diversified technology and manufacturing company, where she also served as Corporate Secretary from January 2018 to September 2019. Prior to that, Ms. Madden was Vice President, Corporate Development and Global Head of M&A at Honeywell for sixteen years. During her tenure, Honeywell made approximately 100 acquisitions representing approximately $15 billion in revenues and divested approximately 70 businesses representing close to $9 billion of non-core revenues. Ms. Madden joined AlliedSignal, Honeywell's predecessor, in 1996 as General Counsel of Fluorine Products and, later that year, became Vice President and General Counsel of Specialty Chemicals and then Vice President and Deputy General Counsel of Performance Materials and Technologies. Earlier in her career, Ms. Madden worked at Shearman & Sterling and KPMG.
Tomislav Mihaljevic

Tomislav Mihaljevic,曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。自2018年1月以来,Mihaljevic博士一直担任Cleveland Clinic(全球综合医疗保健系统)的首席执行官兼总裁,Morton L. Mandel首席执行官主席。从2015年到2017年,他担任Cleveland Clinic Abu Dhabi(“CCAD”)的首席执行官,这是第一家在北美以外复制的美国多专科医院。从2011年到2015年,他担任CCAD心脏和血管研究所的参谋长和主席,领导新医院员工的招聘、招聘和培训。Mihaljevic博士于2004年加入Cleveland Clinic,担任胸心血管外科的外科医生。


Tomislav Mihaljevic,has served as a member of Board since the Spin-Off. Since January 2018, Dr. Mihaljevic has served as the Director, Chief Executive Officer and President, Morton L. Mandel CEO Chair, of Cleveland Clinic, a global integrated healthcare system. From 2015 to 2017, Dr. Mihaljevic served as Chief Executive Officer of Cleveland Clinic Abu Dhabi ("CCAD"), the first U.S. multi-specialty hospital to be replicated outside of North America. From 2011 to 2015, he was Chief of Staff and Chairman of the Heart & Vascular Institute at CCAD, leading the recruitment, hiring, and training of the new hospital's workforce. Dr. Mihaljevic joined Cleveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery.
Tomislav Mihaljevic,曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。自2018年1月以来,Mihaljevic博士一直担任Cleveland Clinic(全球综合医疗保健系统)的首席执行官兼总裁,Morton L. Mandel首席执行官主席。从2015年到2017年,他担任Cleveland Clinic Abu Dhabi(“CCAD”)的首席执行官,这是第一家在北美以外复制的美国多专科医院。从2011年到2015年,他担任CCAD心脏和血管研究所的参谋长和主席,领导新医院员工的招聘、招聘和培训。Mihaljevic博士于2004年加入Cleveland Clinic,担任胸心血管外科的外科医生。
Tomislav Mihaljevic,has served as a member of Board since the Spin-Off. Since January 2018, Dr. Mihaljevic has served as the Director, Chief Executive Officer and President, Morton L. Mandel CEO Chair, of Cleveland Clinic, a global integrated healthcare system. From 2015 to 2017, Dr. Mihaljevic served as Chief Executive Officer of Cleveland Clinic Abu Dhabi ("CCAD"), the first U.S. multi-specialty hospital to be replicated outside of North America. From 2011 to 2015, he was Chief of Staff and Chairman of the Heart & Vascular Institute at CCAD, leading the recruitment, hiring, and training of the new hospital's workforce. Dr. Mihaljevic joined Cleveland Clinic in 2004 as a surgeon in the Department of Thoracic and Cardiovascular Surgery.
Catherine Lesjak

Catherine Lesjak,将被任命为Ge Healthcare Technologies Inc.。与分拆有关的董事会。Lesjak女士在HP Inc.(前Hewlett-Packard Company)(“HP”)32年的职业生涯中担任过各种财务领导职务,于2019年退休。最近,从2018年7月到2019年3月,她担任HP临时首席运营官。2007年1月至2015年11月,她担任HP的执行副总裁兼首席财务官;2015年11月至2018年7月,她担任首席财务官。2010年8月至2010年11月,Lesjak女士担任HP临时首席执行官。在被任命为首席财务官之前,Lesjak女士曾担任HP高级副总裁兼财务主管。在HP职业生涯早期,她曾管理企业营销和解决方案以及软件全球业务部门的财务运营。Lesjak女士担任通用电气公司(纽约证券交易所代码:GE)的董事会成员,在那里她担任审计和治理&公共事务委员会,SunPower Corporation(纳斯达克代码:SPWR),在那里她担任审计委员会主席和薪酬委员会成员,以及PROS Holdings, Inc.(纽约证券交易所代码:PRO),在那里她担任审计委员会主席和提名和公司治理委员会成员。她拥有斯坦福大学(Stanford University)生物学学士学位和加州大学伯克利分校(University of California, Berkeley)金融学工商管理硕士学位。


Catherine Lesjak,was appointed to Board in December 2022 in connection with the Spin-Off. Ms. Lesjak held a broad range of financial leadership roles over a 32-year career at HP Inc. (formerly Hewlett-Packard Company) ("HP"), a multinational information technology company, from which she retired in March 2019. Most recently, from July 2018 until March 2019, she was the interim Chief Operating Officer of HP. From January 2007 to November 2015, Ms. Lesjak was Executive Vice President and Chief Financial Officer of HP, and from November 2015 to July 2018, she was Chief Financial Officer. Ms. Lesjak served as Interim Chief Executive Officer of HP from August 2010 until November 2010. Prior to being named Chief Financial Officer, Ms. Lesjak served as Senior Vice President and Treasurer of HP. Earlier in her career at HP, she managed financial operations for Enterprise Marketing and Solutions and the Software Global Business Unit.
Catherine Lesjak,将被任命为Ge Healthcare Technologies Inc.。与分拆有关的董事会。Lesjak女士在HP Inc.(前Hewlett-Packard Company)(“HP”)32年的职业生涯中担任过各种财务领导职务,于2019年退休。最近,从2018年7月到2019年3月,她担任HP临时首席运营官。2007年1月至2015年11月,她担任HP的执行副总裁兼首席财务官;2015年11月至2018年7月,她担任首席财务官。2010年8月至2010年11月,Lesjak女士担任HP临时首席执行官。在被任命为首席财务官之前,Lesjak女士曾担任HP高级副总裁兼财务主管。在HP职业生涯早期,她曾管理企业营销和解决方案以及软件全球业务部门的财务运营。Lesjak女士担任通用电气公司(纽约证券交易所代码:GE)的董事会成员,在那里她担任审计和治理&公共事务委员会,SunPower Corporation(纳斯达克代码:SPWR),在那里她担任审计委员会主席和薪酬委员会成员,以及PROS Holdings, Inc.(纽约证券交易所代码:PRO),在那里她担任审计委员会主席和提名和公司治理委员会成员。她拥有斯坦福大学(Stanford University)生物学学士学位和加州大学伯克利分校(University of California, Berkeley)金融学工商管理硕士学位。
Catherine Lesjak,was appointed to Board in December 2022 in connection with the Spin-Off. Ms. Lesjak held a broad range of financial leadership roles over a 32-year career at HP Inc. (formerly Hewlett-Packard Company) ("HP"), a multinational information technology company, from which she retired in March 2019. Most recently, from July 2018 until March 2019, she was the interim Chief Operating Officer of HP. From January 2007 to November 2015, Ms. Lesjak was Executive Vice President and Chief Financial Officer of HP, and from November 2015 to July 2018, she was Chief Financial Officer. Ms. Lesjak served as Interim Chief Executive Officer of HP from August 2010 until November 2010. Prior to being named Chief Financial Officer, Ms. Lesjak served as Senior Vice President and Treasurer of HP. Earlier in her career at HP, she managed financial operations for Enterprise Marketing and Solutions and the Software Global Business Unit.
Phoebe L. Yang

Phoebe L. Yang,她将被任命为Ge Healthcare Technologies Inc.的董事—与分拆有关的董事会。她在2020年至2022年期间担任亚马逊网络服务,医疗保健的总经理。在此之前,她曾于2013-2016年在Ascension担任人口健康首席战略官,并于2016年至2018年担任Ascension Holdings International的首席董事总经理。她曾担任The Advisory Board company、Discovery Inc.和AOL Time Warner的上市公司高管,并担任Rock Water Ventures, LLC的董事总经理。她自2022年8月起担任Doximity, Inc.(纽约证券交易所代码:DOCS)的独立董事,Doximity是美国医疗专业人士的领先数字平台,在那里她担任薪酬、提名和治理委员会成员。她也是CommonSpirit Health(美国最大的卫生系统之一)的董事会成员,此前担任Providence St. Joseph Health的董事会成员。她是外交关系委员会(Council on Foreign Relations)的长期成员,并曾在两届美国总统政府中担任国务院和联邦通信委员会(Federal Communications Commission)的任命。她拥有弗吉尼亚大学的文学学士学位和斯坦福大学法学院的法学博士学位。


Phoebe L. Yang,currently serves on the board of directors of each of GE Healthcare Technologies, Inc., a leading global S&P 500 medical technology and solutions company, since January 2023, CommonSpirit Health, one of the largest U.S. tax-exempt health systems, since July 2020. From 2014 to 2020, she served on the board of directors of Providence-St. Joseph Health, one of the largest U.S. tax-exempt health systems. From May 2020 to September 2022, Ms. Yang served as General Manager, Amazon Web Services, Healthcare, where she led Amazon's cloud business focused on enabling healthcare enterprises with advanced cloud technologies. From 2013 to 2018, Ms. Yang served as Chief Strategy Officer and Chief Architect for Population Health at Ascension Health, one of the largest U.S. tax-exempt health systems. A lifetime member of the Council on Foreign Relations since 2002, Ms. Yang holds a B.A. from the University of Virginia, and a J.D. from Stanford Law School, where she was President of the Stanford Law Review.
Phoebe L. Yang,她将被任命为Ge Healthcare Technologies Inc.的董事—与分拆有关的董事会。她在2020年至2022年期间担任亚马逊网络服务,医疗保健的总经理。在此之前,她曾于2013-2016年在Ascension担任人口健康首席战略官,并于2016年至2018年担任Ascension Holdings International的首席董事总经理。她曾担任The Advisory Board company、Discovery Inc.和AOL Time Warner的上市公司高管,并担任Rock Water Ventures, LLC的董事总经理。她自2022年8月起担任Doximity, Inc.(纽约证券交易所代码:DOCS)的独立董事,Doximity是美国医疗专业人士的领先数字平台,在那里她担任薪酬、提名和治理委员会成员。她也是CommonSpirit Health(美国最大的卫生系统之一)的董事会成员,此前担任Providence St. Joseph Health的董事会成员。她是外交关系委员会(Council on Foreign Relations)的长期成员,并曾在两届美国总统政府中担任国务院和联邦通信委员会(Federal Communications Commission)的任命。她拥有弗吉尼亚大学的文学学士学位和斯坦福大学法学院的法学博士学位。
Phoebe L. Yang,currently serves on the board of directors of each of GE Healthcare Technologies, Inc., a leading global S&P 500 medical technology and solutions company, since January 2023, CommonSpirit Health, one of the largest U.S. tax-exempt health systems, since July 2020. From 2014 to 2020, she served on the board of directors of Providence-St. Joseph Health, one of the largest U.S. tax-exempt health systems. From May 2020 to September 2022, Ms. Yang served as General Manager, Amazon Web Services, Healthcare, where she led Amazon's cloud business focused on enabling healthcare enterprises with advanced cloud technologies. From 2013 to 2018, Ms. Yang served as Chief Strategy Officer and Chief Architect for Population Health at Ascension Health, one of the largest U.S. tax-exempt health systems. A lifetime member of the Council on Foreign Relations since 2002, Ms. Yang holds a B.A. from the University of Virginia, and a J.D. from Stanford Law School, where she was President of the Stanford Law Review.
Rodney F. Hochman

Rodney F. Hochman,他曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。自2016年以来,他一直担任普罗维登斯(一个天主教非营利卫生系统)的总裁兼首席执行官。他还担任普罗维登斯的董事会成员。从2013年到2016年,他担任Providence Health & Services, Inc.的总裁兼首席执行官,该公司于2016年与St. Joseph Health合并,成立Providence St. Joseph Health(现为Providence)。在此之前,他从2007年到2012年担任Swedish Medical Center的总裁兼首席执行官。从1998年到2007年,Hochman博士在Sentara Health System担任各种领导职务。他是美国医院协会和天主教健康协会的前任主席。


Rodney F. Hochman,has served as a member of Board since the Spin-Off. Dr. Hochman has served as Senior Advisor, Healthcare at Bain Capital, LP, a private investment firm, and Chief Executive Officer Emeritus of Providence, a Catholic not-for-profit health system, since January 2025. From 2016 through December 2024, Dr. Hochman served as the President and Chief Executive Officer of Providence. Dr. Hochman also served as a member of the board of Providence until his retirement in December 2024. From 2013 to 2016, he served as the President and Chief Executive Officer of Providence Health & Services, Inc., which merged with St. Joseph Health to form Providence St. Joseph Health (now Providence) in 2016. Before that, he served as the President and Chief Executive Officer of Swedish Medical Center from 2007 to 2012. From 1998 to 2007, Dr. Hochman held various leadership roles within the Sentara Health System. He is former Chair of the American Hospital Association and the Catholic Health Association.
Rodney F. Hochman,他曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。自2016年以来,他一直担任普罗维登斯(一个天主教非营利卫生系统)的总裁兼首席执行官。他还担任普罗维登斯的董事会成员。从2013年到2016年,他担任Providence Health & Services, Inc.的总裁兼首席执行官,该公司于2016年与St. Joseph Health合并,成立Providence St. Joseph Health(现为Providence)。在此之前,他从2007年到2012年担任Swedish Medical Center的总裁兼首席执行官。从1998年到2007年,Hochman博士在Sentara Health System担任各种领导职务。他是美国医院协会和天主教健康协会的前任主席。
Rodney F. Hochman,has served as a member of Board since the Spin-Off. Dr. Hochman has served as Senior Advisor, Healthcare at Bain Capital, LP, a private investment firm, and Chief Executive Officer Emeritus of Providence, a Catholic not-for-profit health system, since January 2025. From 2016 through December 2024, Dr. Hochman served as the President and Chief Executive Officer of Providence. Dr. Hochman also served as a member of the board of Providence until his retirement in December 2024. From 2013 to 2016, he served as the President and Chief Executive Officer of Providence Health & Services, Inc., which merged with St. Joseph Health to form Providence St. Joseph Health (now Providence) in 2016. Before that, he served as the President and Chief Executive Officer of Swedish Medical Center from 2007 to 2012. From 1998 to 2007, Dr. Hochman held various leadership roles within the Sentara Health System. He is former Chair of the American Hospital Association and the Catholic Health Association.
William J. Stromberg

William J. Stromberg,曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。2016年1月以来,他一直担任T. Rowe Price Group, Inc.(“Price Group”)(一家全球投资管理公司)的董事,并自2021年12月以来担任Price Group董事会的非执行主席。他计划于2024年5月从Price Group董事会退休。他曾担任Price Group的首席执行官(2016年1月至2021年12月),以及总裁(2016年至2021年2月)。在此之前,他从2009年到2015年担任Price Group的股权主管,从2006年到2009年担任美国股权主管。在Price Group的职业生涯早期,他曾担任股票研究总监和投资组合经理。在1987年加入Price Group之前,他受雇于Westinghouse Defense,担任系统工程师。


William J. Stromberg,has served as a member of Board since the Spin-Off. Mr. Stromberg served as Interim Chief Investment Officer at Johns Hopkins University from June 2024 to February 2025. From January 2016 through May 2024, Mr. Stromberg was a director of the T. Rowe Price Group, Inc. ("Price Group"), a global investment management firm, and served as the Non-executive Chair of the Price Group board from December 2021 through his retirement from the Price Group board in May 2024. Mr. Stromberg served as the Chief Executive Officer of Price Group from January 2016 to December 2021 and was its President from 2016 to February 2021. Prior to that, Mr. Stromberg was Price Group's Head of Equity from 2009 to 2015 and the Head of U.S. Equity from 2006 to 2009. Earlier in his career at Price Group, he served as a Director of Equity Research and as a portfolio manager. Before joining Price Group in 1987, he was employed by Westinghouse Defense as a systems engineer.
William J. Stromberg,曾担任Ge Healthcare Technologies Inc.的成员。自分拆以来担任董事会成员。2016年1月以来,他一直担任T. Rowe Price Group, Inc.(“Price Group”)(一家全球投资管理公司)的董事,并自2021年12月以来担任Price Group董事会的非执行主席。他计划于2024年5月从Price Group董事会退休。他曾担任Price Group的首席执行官(2016年1月至2021年12月),以及总裁(2016年至2021年2月)。在此之前,他从2009年到2015年担任Price Group的股权主管,从2006年到2009年担任美国股权主管。在Price Group的职业生涯早期,他曾担任股票研究总监和投资组合经理。在1987年加入Price Group之前,他受雇于Westinghouse Defense,担任系统工程师。
William J. Stromberg,has served as a member of Board since the Spin-Off. Mr. Stromberg served as Interim Chief Investment Officer at Johns Hopkins University from June 2024 to February 2025. From January 2016 through May 2024, Mr. Stromberg was a director of the T. Rowe Price Group, Inc. ("Price Group"), a global investment management firm, and served as the Non-executive Chair of the Price Group board from December 2021 through his retirement from the Price Group board in May 2024. Mr. Stromberg served as the Chief Executive Officer of Price Group from January 2016 to December 2021 and was its President from 2016 to February 2021. Prior to that, Mr. Stromberg was Price Group's Head of Equity from 2009 to 2015 and the Head of U.S. Equity from 2006 to 2009. Earlier in his career at Price Group, he served as a Director of Equity Research and as a portfolio manager. Before joining Price Group in 1987, he was employed by Westinghouse Defense as a systems engineer.

高管简历

中英对照 |  中文 |  英文
Kevin M. O'Neill

Kevin M. O'Neill,O’Neill先生因分拆而被任命为Ge Healthcare Technologies Inc.的医药诊断首席执行官,从2017年到分拆,他一直担任GE医疗业务的医药诊断首席执行官。自2018年起,O'Neill还担任通用GE Ireland和英国公司的总裁兼首席执行官。在此之前,他于2013年8月起担任GE 医疗保健业务生命科学部门的首席财务官。O'Neill在GE 拥有20多年的工作经验,最初在英国和美国从事能源服务业务。紧随其后的是通用电气医疗保健业务的一系列CFO职位,包括生命科学、供应链、西欧以及PDx业务。在加入GE 之前,O'Neill是欧洲高速列车运营商欧洲之星的财务总监。他拥有伦敦城市大学的工商管理硕士学位,并且是英国特许管理会计师协会的会员。


Kevin M. O'Neill,has served as President and Chief Executive Officer, Pharmaceutical Diagnostics since the Spin-Off. He served as Chief Executive Officer, Pharmaceutical Diagnostics of GE's healthcare business from July 2017 until the Spin-Off and served as President and Chief Executive Officer, GE Ireland and U.K., from January 2018 until the Spin-Off. Prior to that, he was the Chief Financial Officer of the Life Sciences division of GE's healthcare business starting in August 2013. Mr. O'Neill has over 20 years of experience with GE, beginning in the Energy services business in the U.K. and U.S. followed by a series of chief financial officer roles in GE's healthcare business, including in the Life Sciences business, supply chain, Western Europe, and the PDx business. Prior to joining GE, Mr. O'Neill was Financial Controller for Eurostar, the European high-speed train operator.
Kevin M. O'Neill,O’Neill先生因分拆而被任命为Ge Healthcare Technologies Inc.的医药诊断首席执行官,从2017年到分拆,他一直担任GE医疗业务的医药诊断首席执行官。自2018年起,O'Neill还担任通用GE Ireland和英国公司的总裁兼首席执行官。在此之前,他于2013年8月起担任GE 医疗保健业务生命科学部门的首席财务官。O'Neill在GE 拥有20多年的工作经验,最初在英国和美国从事能源服务业务。紧随其后的是通用电气医疗保健业务的一系列CFO职位,包括生命科学、供应链、西欧以及PDx业务。在加入GE 之前,O'Neill是欧洲高速列车运营商欧洲之星的财务总监。他拥有伦敦城市大学的工商管理硕士学位,并且是英国特许管理会计师协会的会员。
Kevin M. O'Neill,has served as President and Chief Executive Officer, Pharmaceutical Diagnostics since the Spin-Off. He served as Chief Executive Officer, Pharmaceutical Diagnostics of GE's healthcare business from July 2017 until the Spin-Off and served as President and Chief Executive Officer, GE Ireland and U.K., from January 2018 until the Spin-Off. Prior to that, he was the Chief Financial Officer of the Life Sciences division of GE's healthcare business starting in August 2013. Mr. O'Neill has over 20 years of experience with GE, beginning in the Energy services business in the U.K. and U.S. followed by a series of chief financial officer roles in GE's healthcare business, including in the Life Sciences business, supply chain, Western Europe, and the PDx business. Prior to joining GE, Mr. O'Neill was Financial Controller for Eurostar, the European high-speed train operator.
Roland Rott

Roland Rott,自2024年7月起担任Imaging总裁兼首席执行官。在此之前,罗特先生曾担任GE Healthcare Technologies Inc.首席执行官,自分拆至2024年6月担任Ultrasound。他于2021年4月起担任GE 医疗保健业务的超声业务首席执行官,直至分拆完成。Rott先生于2011年加入GE的医疗保健业务,曾担任多个领导职务,包括在全球女性健康超声和超声IT领域以及孕产妇和婴儿护理领域。在加入GE之前,罗特先生是欧洲、中东、非洲和亚太地区的董事总经理,以及Exact Holding的执行董事会成员。在他早期的职业生涯中,他有一个创业的开始,在奥地利创立并成功退出了两家软件公司。


Roland Rott,has served as President and Chief Executive Officer, Imaging since July 2024. Prior to that, Mr. Rott served as Ge Healthcare Technologies Inc. Chief Executive Officer, Ultrasound from the Spin-Off to June 2024. He served as Chief Executive Officer, Ultrasound of GE's healthcare business from April 2021 until the Spin-Off. Mr. Rott joined GE's healthcare business in 2011 and has held several leadership roles including in the global Women's Health Ultrasound and Ultrasound IT segments as well as Maternal Infant Care. Before joining GE, Mr. Rott was Managing Director, Europe, the Middle East, and Africa and Asia Pacific, and Executive Board Member of Exact Holding. In his early career, he had an entrepreneurial start, founding and successfully exiting two software companies in Austria.
Roland Rott,自2024年7月起担任Imaging总裁兼首席执行官。在此之前,罗特先生曾担任GE Healthcare Technologies Inc.首席执行官,自分拆至2024年6月担任Ultrasound。他于2021年4月起担任GE 医疗保健业务的超声业务首席执行官,直至分拆完成。Rott先生于2011年加入GE的医疗保健业务,曾担任多个领导职务,包括在全球女性健康超声和超声IT领域以及孕产妇和婴儿护理领域。在加入GE之前,罗特先生是欧洲、中东、非洲和亚太地区的董事总经理,以及Exact Holding的执行董事会成员。在他早期的职业生涯中,他有一个创业的开始,在奥地利创立并成功退出了两家软件公司。
Roland Rott,has served as President and Chief Executive Officer, Imaging since July 2024. Prior to that, Mr. Rott served as Ge Healthcare Technologies Inc. Chief Executive Officer, Ultrasound from the Spin-Off to June 2024. He served as Chief Executive Officer, Ultrasound of GE's healthcare business from April 2021 until the Spin-Off. Mr. Rott joined GE's healthcare business in 2011 and has held several leadership roles including in the global Women's Health Ultrasound and Ultrasound IT segments as well as Maternal Infant Care. Before joining GE, Mr. Rott was Managing Director, Europe, the Middle East, and Africa and Asia Pacific, and Executive Board Member of Exact Holding. In his early career, he had an entrepreneurial start, founding and successfully exiting two software companies in Austria.
Thomas J. Westrick

Thomas J. Westrick,因分拆而被任命为Ge Healthcare Technologies Inc.患者护理解决方案首席执行官,在分拆之前,他自2020年起担任GE医疗业务的患者护理解决方案首席执行官。此前,他曾于2016年1月至2020年9月领导GE医疗保健业务的全球质量、医疗、监管事务和全球研究组织。Westrick先生于2003年加入GE的医疗保健业务,担任全球财务总监和首席会计官。2010年,他还被任命为首席风险官,负责领导一个全面的企业风险管理项目。在加入GE的医疗保健业务之前,Westrick曾在Arthur Andersen LLP和Deloitte & Touche LLP从事公共会计工作13年,从事审计和咨询业务,为各种复杂的全球公司提供服务。他目前在Wisconsin School of Business的院长顾问委员会任职。Westrick先生拥有Wisconsin-Madison大学麦迪逊分校的会计、风险管理和保险学士学位。


Thomas J. Westrick,has served as President and Chief Executive Officer, Patient Care Solutions since the Spin-Off. He served as Chief Executive Officer, Patient Care Solutions of GE's healthcare business from September 2020 until the Spin-Off. Previously, he led the Global Quality, Medical, Regulatory Affairs and Global Research organization for GE's healthcare business from January 2016 to September 2020. Mr. Westrick joined GE's healthcare business in 2003 as Global Controller and Chief Accounting Officer. He was also named Chief Risk Officer in 2010 and was responsible for leading a comprehensive enterprise risk management program. Prior to joining GE's healthcare business, Mr. Westrick spent 13 years in public accounting with Arthur Andersen LLP and Deloitte & Touche LLP in the audit and consulting practice serving a variety of complex global companies.
Thomas J. Westrick,因分拆而被任命为Ge Healthcare Technologies Inc.患者护理解决方案首席执行官,在分拆之前,他自2020年起担任GE医疗业务的患者护理解决方案首席执行官。此前,他曾于2016年1月至2020年9月领导GE医疗保健业务的全球质量、医疗、监管事务和全球研究组织。Westrick先生于2003年加入GE的医疗保健业务,担任全球财务总监和首席会计官。2010年,他还被任命为首席风险官,负责领导一个全面的企业风险管理项目。在加入GE的医疗保健业务之前,Westrick曾在Arthur Andersen LLP和Deloitte & Touche LLP从事公共会计工作13年,从事审计和咨询业务,为各种复杂的全球公司提供服务。他目前在Wisconsin School of Business的院长顾问委员会任职。Westrick先生拥有Wisconsin-Madison大学麦迪逊分校的会计、风险管理和保险学士学位。
Thomas J. Westrick,has served as President and Chief Executive Officer, Patient Care Solutions since the Spin-Off. He served as Chief Executive Officer, Patient Care Solutions of GE's healthcare business from September 2020 until the Spin-Off. Previously, he led the Global Quality, Medical, Regulatory Affairs and Global Research organization for GE's healthcare business from January 2016 to September 2020. Mr. Westrick joined GE's healthcare business in 2003 as Global Controller and Chief Accounting Officer. He was also named Chief Risk Officer in 2010 and was responsible for leading a comprehensive enterprise risk management program. Prior to joining GE's healthcare business, Mr. Westrick spent 13 years in public accounting with Arthur Andersen LLP and Deloitte & Touche LLP in the audit and consulting practice serving a variety of complex global companies.
Philip Rackliffe

Philip Rackliffe,曾担任Ge Healthcare Technologies Inc.的总裁兼首席执行官。IGT业务从2022年8月到2024年6月。从2019年10月到2022年8月,他担任Centerline Biomedical(生物医学设备和成像公司)的首席执行官。他在医疗技术、医疗设备、成像和制药公司(包括公共和私人公司)拥有超过25年的全球经验,包括Baxter、Boston Scientific和Pfizer。


Philip Rackliffe,has served as President and Chief Executive Officer, Advanced Visualization Solutions since July 2024. Previously, Mr. Rackliffe served as President and Chief Executive Officer of Ge Healthcare Technologies Inc. IGT business from August 2022 to June 2024. From October 2019 to August 2022, Mr. Rackliffe served as the Chief Executive Officer of Centerline Biomedical, a biomedical device and imaging company. He has over 25 years of global experience in medtech, medical device, imaging and pharmaceutical companies, both public and private, including Baxter, Boston Scientific, and Pfizer.
Philip Rackliffe,曾担任Ge Healthcare Technologies Inc.的总裁兼首席执行官。IGT业务从2022年8月到2024年6月。从2019年10月到2022年8月,他担任Centerline Biomedical(生物医学设备和成像公司)的首席执行官。他在医疗技术、医疗设备、成像和制药公司(包括公共和私人公司)拥有超过25年的全球经验,包括Baxter、Boston Scientific和Pfizer。
Philip Rackliffe,has served as President and Chief Executive Officer, Advanced Visualization Solutions since July 2024. Previously, Mr. Rackliffe served as President and Chief Executive Officer of Ge Healthcare Technologies Inc. IGT business from August 2022 to June 2024. From October 2019 to August 2022, Mr. Rackliffe served as the Chief Executive Officer of Centerline Biomedical, a biomedical device and imaging company. He has over 25 years of global experience in medtech, medical device, imaging and pharmaceutical companies, both public and private, including Baxter, Boston Scientific, and Pfizer.
Peter J. Arduini

Peter J. Arduini,Integra的总裁、首席执行官及董事。他于2010年11月加入Integra担任总裁兼首席营运官,于2012年1月被任命为首席执行官兼董事。在加入Integra之前,他曾于2005年加入Baxter Healthcare并担任企业副总裁及药物输注部总裁。他负责Baxter一个市值48亿美元的全球部门。在加入Baxter之前,他受雇于 General Electric Healthcare,担任了一系列国内外业务的管理职务,最近担任GE Healthcare公司的全球总经理,负责计算机轴向断层扫描(CT)和功能成像业务。在加入 General Electric Healthcare之前,他在宝洁(Procter and Gamble)工作了4年,从事销售和营销工作。他在先进医疗技术协会(ADVAMED)和国家意大利裔美国基金会(the National Italian American Foundation)的董事会任职。他持有Susquehanna University 的营销学学士学位和西北大学凯洛格管理学院( Northwestern University's Kellogg School of Management)的管理学硕士学位。


Peter J. Arduini,was appointed as President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE's healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences ("Integra"), a global medical technology company, from January 2012 to December 2021. During his tenure as Integra's Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE's healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales.
Peter J. Arduini,Integra的总裁、首席执行官及董事。他于2010年11月加入Integra担任总裁兼首席营运官,于2012年1月被任命为首席执行官兼董事。在加入Integra之前,他曾于2005年加入Baxter Healthcare并担任企业副总裁及药物输注部总裁。他负责Baxter一个市值48亿美元的全球部门。在加入Baxter之前,他受雇于 General Electric Healthcare,担任了一系列国内外业务的管理职务,最近担任GE Healthcare公司的全球总经理,负责计算机轴向断层扫描(CT)和功能成像业务。在加入 General Electric Healthcare之前,他在宝洁(Procter and Gamble)工作了4年,从事销售和营销工作。他在先进医疗技术协会(ADVAMED)和国家意大利裔美国基金会(the National Italian American Foundation)的董事会任职。他持有Susquehanna University 的营销学学士学位和西北大学凯洛格管理学院( Northwestern University's Kellogg School of Management)的管理学硕士学位。
Peter J. Arduini,was appointed as President and Chief Executive Officer in connection with the Spin-Off, and he has also served as a member of the Board since the Spin-Off. He served as the President and Chief Executive Officer of GE's healthcare business from January 2022 until December 2022. Previously, Mr. Arduini was the President and Chief Executive Officer of Integra LifeSciences ("Integra"), a global medical technology company, from January 2012 to December 2021. During his tenure as Integra's Chief Executive Officer, the Integra portfolio evolved significantly to a faster growing and more profitable company through multiple acquisitions and a sustainable research and development pipeline. Prior to Integra, Mr. Arduini worked at Baxter Healthcare as President of its Medication Delivery division. Before Baxter Healthcare, he spent 15 years at GE's healthcare business in a variety of leadership roles in the United States and globally, including leading the Computed Tomography and Molecular Imaging business, Healthcare Services and U.S. sales.
James K. Saccaro

James K. Saccaro是公司副总裁兼首席财务官,自2015年6月起一直担任此职务。2013年12月至2014年7月,Saccaro先生是Hill-Rom公司的高级副总裁和首席财政官。2014年7月加入Baxter之前,担任首席执行官的特别顾问。在此之前,2011年至2013年Saccaro先生曾担任Baxter公司的副总裁兼财务主管。2002年他最初加入该公司,担任公司前任生物科学业务的战略经理,并从那里担任越来越重要的职务,其中包括欧洲、中东和非洲业务的财务规划和财务副总裁。Baxter之前,他在Clear Channel Communications和Walt Disney Company担任战略和业务发展的职务。


James K. Saccaro,has served as Vice President and Chief Financial Officer since June 2023. Previously, Mr. Saccaro served as the Chief Financial Officer of Baxter International Inc. (NYSE: BAX) ("Baxter"), a multinational healthcare company, starting in 2015. He held a variety of positions of increasing responsibility at Baxter from 2002 through 2013, including Vice President of Financial Planning and Analysis; Vice President of Finance for Baxter's operations in Europe, the Middle East, and Africa; Vice President of Strategy; and Corporate Vice President and Treasurer. Mr. Saccaro served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc. from 2013 to 2014 prior to rejoining Baxter as Special Assistant to the Chief Executive Officer in 2014. Prior to Baxter, he held strategy and business development positions at Clear Channel Communications and The Walt Disney Company.
James K. Saccaro是公司副总裁兼首席财务官,自2015年6月起一直担任此职务。2013年12月至2014年7月,Saccaro先生是Hill-Rom公司的高级副总裁和首席财政官。2014年7月加入Baxter之前,担任首席执行官的特别顾问。在此之前,2011年至2013年Saccaro先生曾担任Baxter公司的副总裁兼财务主管。2002年他最初加入该公司,担任公司前任生物科学业务的战略经理,并从那里担任越来越重要的职务,其中包括欧洲、中东和非洲业务的财务规划和财务副总裁。Baxter之前,他在Clear Channel Communications和Walt Disney Company担任战略和业务发展的职务。
James K. Saccaro,has served as Vice President and Chief Financial Officer since June 2023. Previously, Mr. Saccaro served as the Chief Financial Officer of Baxter International Inc. (NYSE: BAX) ("Baxter"), a multinational healthcare company, starting in 2015. He held a variety of positions of increasing responsibility at Baxter from 2002 through 2013, including Vice President of Financial Planning and Analysis; Vice President of Finance for Baxter's operations in Europe, the Middle East, and Africa; Vice President of Strategy; and Corporate Vice President and Treasurer. Mr. Saccaro served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc. from 2013 to 2014 prior to rejoining Baxter as Special Assistant to the Chief Executive Officer in 2014. Prior to Baxter, he held strategy and business development positions at Clear Channel Communications and The Walt Disney Company.
Taha Kass Hout

Taha Kass Hout博士,医学博士,MS,自2023年1月起担任GE Healthcare的首席技术官,领导公司的科技组织,并努力通过临床研究以及数字和机器学习能力的发展推动增长。此前,Kass-Hout博士曾于2017年5月至2023年1月担任亚马逊机器学习副总裁、杰出工程师和首席医疗官,领导公司的云健康AI战略、产品和服务,并且是亚马逊健康计划的主要贡献者,包括药房和诊断。2020年,他在亚马逊领导团队,负责为亚马逊的新冠肺炎实验室开发科学、技术和规模,包括亚马逊首次获得FDA授权,在全球范围内对其员工进行检测——后来向公众提供了在家检测的服务。2013年至2016年,Kass-Hout博士还担任了FDA的首位首席健康信息官,领导了总裁的精准医学计划PrecisionFDA。Kass-Hout博士拥有休斯顿得克萨斯大学健康科学中心的医学博士和生物统计学硕士学位,并在哈佛医学院的贝斯以色列女执事医疗中心完成了介入心脏病学的临床培训。


Taha Kass Hout,has served as GE HealthCare's Global Chief Science and Technology Officer since January 2023. Merging his background in interventional cardiology with AI and machine learning, he is driving advancements in AI-based medical imaging, diagnostics, and health system operational efficiency. Prior to his role at GE HealthCare, Dr. Kass-Hout served as Vice President of Machine Learning, Distinguished Engineer, and Chief Medical Officer at Amazon from May 2017 to January 2023, where he led the company's health AI strategy, technologies and solutions, including Amazon Comprehend Medical, AWS HealthLake, and Amazon Pharmacy. He also played a critical role in establishing Amazon's COVID-19 diagnostics lab, including Amazon's first U.S. FDA authorization for testing its associates globally—later offered to the public for at-home testing. From 2013 to 2016, Dr. Kass-Hout was the first Chief Health Informatics Officer at the FDA, where he championed data transparency through initiatives including openFDA and precisionFDA. Dr. Kass-Hout is also the current Chair of the AdvaMed Digital Health Tech Division Board of Directors.
Taha Kass Hout博士,医学博士,MS,自2023年1月起担任GE Healthcare的首席技术官,领导公司的科技组织,并努力通过临床研究以及数字和机器学习能力的发展推动增长。此前,Kass-Hout博士曾于2017年5月至2023年1月担任亚马逊机器学习副总裁、杰出工程师和首席医疗官,领导公司的云健康AI战略、产品和服务,并且是亚马逊健康计划的主要贡献者,包括药房和诊断。2020年,他在亚马逊领导团队,负责为亚马逊的新冠肺炎实验室开发科学、技术和规模,包括亚马逊首次获得FDA授权,在全球范围内对其员工进行检测——后来向公众提供了在家检测的服务。2013年至2016年,Kass-Hout博士还担任了FDA的首位首席健康信息官,领导了总裁的精准医学计划PrecisionFDA。Kass-Hout博士拥有休斯顿得克萨斯大学健康科学中心的医学博士和生物统计学硕士学位,并在哈佛医学院的贝斯以色列女执事医疗中心完成了介入心脏病学的临床培训。
Taha Kass Hout,has served as GE HealthCare's Global Chief Science and Technology Officer since January 2023. Merging his background in interventional cardiology with AI and machine learning, he is driving advancements in AI-based medical imaging, diagnostics, and health system operational efficiency. Prior to his role at GE HealthCare, Dr. Kass-Hout served as Vice President of Machine Learning, Distinguished Engineer, and Chief Medical Officer at Amazon from May 2017 to January 2023, where he led the company's health AI strategy, technologies and solutions, including Amazon Comprehend Medical, AWS HealthLake, and Amazon Pharmacy. He also played a critical role in establishing Amazon's COVID-19 diagnostics lab, including Amazon's first U.S. FDA authorization for testing its associates globally—later offered to the public for at-home testing. From 2013 to 2016, Dr. Kass-Hout was the first Chief Health Informatics Officer at the FDA, where he championed data transparency through initiatives including openFDA and precisionFDA. Dr. Kass-Hout is also the current Chair of the AdvaMed Digital Health Tech Division Board of Directors.
Kenneth Stacherski

Kenneth Stacherski先生自2022年10月起担任GE Healthcare的首席全球供应链和服务官。在加入GE Healthcare之前,他曾于2021年7月至2022年10月担任Array Technologies首席运营官,领导公司实施全球综合供应链战略,包括采购、制造、运营、物流、规划、质量和业务系统。在加入Array Technologies之前,Stacherski先生曾在Honeywell担任多个领导职务超过十年,包括:2019年10月至2021年6月担任综合供应链副总裁;2018年11月至2019年10月担任企业数字化转型副总裁;2017年10月至2018年10月担任投资组合转型副总裁;2016年4月至2017年10月担任Honeywell UOP副总裁兼总经理;2013年5月至2016年4月担任采购、物流和贸易合规副总裁;2011年6月至2013年5月担任综合供应链全球总监。在Honeywell之前,他担任Composite技术公司总裁兼首席运营官,在Ford Motor Company工作了13年。他拥有凯特林大学机械工程学士学位和韦恩州立大学工程管理硕士学位。


Kenneth Stacherski,has served as the Chief Global Supply Chain and Service Officer of GE HealthCare since the Spin-Off. He served as the Chief Global Supply Chain and Service Officer of GE's healthcare business from October 2022 until the Spin-Off. Previously, from July 2021 to October 2022 he served as the Chief Operations Officer of Array Technologies, a solar tracking company, where he led the company's global integrated supply chain strategy. Before joining Array Technologies, Mr. Stacherski served for over ten years in various leadership roles with Honeywell, a diversified technology and manufacturing company, including Vice President of Integrated Supply Chain from October 2019 to June 2021; Vice President of Enterprise Digital Transformation from November 2018 to October 2019; Vice President of Portfolio Transformation from October 2017 to October 2018; Vice President and General Manager of Honeywell UOP from April 2016 to October 2017; Vice President of Procurement, Logistics, and Trade Compliance from May 2013 to April 2016; and Global Director of Integrated Supply Chain from June 2011 to May 2013. Prior to Honeywell, he acted as President and Chief Operating Officer of Composite Technologies Corporation and spent 13 years at Ford Motor Company.
Kenneth Stacherski先生自2022年10月起担任GE Healthcare的首席全球供应链和服务官。在加入GE Healthcare之前,他曾于2021年7月至2022年10月担任Array Technologies首席运营官,领导公司实施全球综合供应链战略,包括采购、制造、运营、物流、规划、质量和业务系统。在加入Array Technologies之前,Stacherski先生曾在Honeywell担任多个领导职务超过十年,包括:2019年10月至2021年6月担任综合供应链副总裁;2018年11月至2019年10月担任企业数字化转型副总裁;2017年10月至2018年10月担任投资组合转型副总裁;2016年4月至2017年10月担任Honeywell UOP副总裁兼总经理;2013年5月至2016年4月担任采购、物流和贸易合规副总裁;2011年6月至2013年5月担任综合供应链全球总监。在Honeywell之前,他担任Composite技术公司总裁兼首席运营官,在Ford Motor Company工作了13年。他拥有凯特林大学机械工程学士学位和韦恩州立大学工程管理硕士学位。
Kenneth Stacherski,has served as the Chief Global Supply Chain and Service Officer of GE HealthCare since the Spin-Off. He served as the Chief Global Supply Chain and Service Officer of GE's healthcare business from October 2022 until the Spin-Off. Previously, from July 2021 to October 2022 he served as the Chief Operations Officer of Array Technologies, a solar tracking company, where he led the company's global integrated supply chain strategy. Before joining Array Technologies, Mr. Stacherski served for over ten years in various leadership roles with Honeywell, a diversified technology and manufacturing company, including Vice President of Integrated Supply Chain from October 2019 to June 2021; Vice President of Enterprise Digital Transformation from November 2018 to October 2019; Vice President of Portfolio Transformation from October 2017 to October 2018; Vice President and General Manager of Honeywell UOP from April 2016 to October 2017; Vice President of Procurement, Logistics, and Trade Compliance from May 2013 to April 2016; and Global Director of Integrated Supply Chain from June 2011 to May 2013. Prior to Honeywell, he acted as President and Chief Operating Officer of Composite Technologies Corporation and spent 13 years at Ford Motor Company.
George A. Newcomb
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Adam Y. Holton

Adam Y. Holton,从2022年10月到2024年6月,担任家庭健康公司Amedisys的首席人事官。在此之前,他于2019年2月至2022年10月担任Numotion(康复技术提供商)的首席人力资源官。Holton先生还曾担任USAA(金融服务公司)人力资源高级副总裁,CHS Inc.(财富100强农业合作社)首席人力资源官。在职业生涯早期,他曾在GE工作,包括GE的医疗保健业务。他自2018年2月起担任Sierra Delta董事会成员,并于2018年11月至2023年11月担任董事会主席。


Adam Y. Holton,has served as Chief People Officer since June 2024. Previously, Mr. Holton served as Chief People Officer of Amedisys, a home health company, from October 2022 to June 2024. Prior to that role, he served as Chief Human Resources Officer at Numotion, a provider of rehab technology from February 2019 to October 2022. Mr. Holton also previously worked as Senior Vice President of Human Resources at USAA, a financial services company and as Chief Human Resources Officer at CHS Inc., a Fortune-100 agricultural cooperative. Earlier in his career, Mr. Holton worked at GE, including GE's healthcare business. He has served on the Board of Sierra Delta since February 2018 and served as Board Chair from November 2018 until November 2023.
Adam Y. Holton,从2022年10月到2024年6月,担任家庭健康公司Amedisys的首席人事官。在此之前,他于2019年2月至2022年10月担任Numotion(康复技术提供商)的首席人力资源官。Holton先生还曾担任USAA(金融服务公司)人力资源高级副总裁,CHS Inc.(财富100强农业合作社)首席人力资源官。在职业生涯早期,他曾在GE工作,包括GE的医疗保健业务。他自2018年2月起担任Sierra Delta董事会成员,并于2018年11月至2023年11月担任董事会主席。
Adam Y. Holton,has served as Chief People Officer since June 2024. Previously, Mr. Holton served as Chief People Officer of Amedisys, a home health company, from October 2022 to June 2024. Prior to that role, he served as Chief Human Resources Officer at Numotion, a provider of rehab technology from February 2019 to October 2022. Mr. Holton also previously worked as Senior Vice President of Human Resources at USAA, a financial services company and as Chief Human Resources Officer at CHS Inc., a Fortune-100 agricultural cooperative. Earlier in his career, Mr. Holton worked at GE, including GE's healthcare business. He has served on the Board of Sierra Delta since February 2018 and served as Board Chair from November 2018 until November 2023.
Frank R. Jimenez

Frank R. Jimenez自2022年2月起担任医疗器械制造和制药公司GE Healthcare的总法律顾问,并在通用电气公司分拆出TERM3后自2023年1月起担任公司秘书。自2020年4月至担任现职,Jimenez先生担任雷神技术公司执行副总裁兼总法律顾问(2020年4月至2021年12月)以及董事长兼首席执行官特别顾问(2021年12月至2022年2月)。自2015年1月至2020年4月与联合技术公司合并,担任雷神公司副总裁、总法律顾问和公司秘书。2012年7月至2015年1月,Jimenez先生担任农业综合企业和食品公司Bunge Limited的公司事务总法律顾问、秘书和董事总经理。此前,他曾担任ITT公司副总裁兼总法律顾问,并在ITT公司的衍生公司Xylem Inc.担任高级副总裁、总法律顾问和公司秘书。在此前的公共服务中,希门尼斯先生曾担任第21任海军总法律顾问、美国国防部副总法律顾问(法律顾问)、海军首席副总法律顾问、美国住房和城市发展部部长Mel Martinez的参谋长,以及佛罗里达州州长杰布·布什的副参谋长和代理总法律顾问。在进入政府部门服务之前,Jimenez先生是Steel Hector and Davis LLP(现为Squire Patton Boggs LLP)的诉讼合伙人。他的法律生涯始于加利福尼亚州帕萨迪纳市美国第九巡回上诉法院法官帕梅拉·安·赖默的内庭担任书记员。希门尼斯过去和现在的公民服务包括迈阿密大学、Equal Justice Works、Pro Bono Partnership、大西洋法律基金会、哥伦比亚大学梅尔曼公共卫生学院、耶鲁法学院基金、耶鲁法学院协会、耶鲁法学院公司法研究中心、PioneerLegal和迈阿密基督教学校的董事会成员。希门尼斯获得了迈阿密大学的学士学位和耶鲁大学法学院的法学博士学位。他还获得了宾夕法尼亚大学沃顿商学院金融和战略管理硕士学位和美国海军战争学院国家安全和战略研究硕士学位,重点是武装冲突法。希门尼斯获准在佛罗里达州、哥伦比亚特区、纽约州和美国最高法院任职。


Frank R. Jimenez,has served as General Counsel and Corporate Secretary since Spin-Off from GE. He served as the General Counsel of GE's healthcare business from February 2022 until the Spin-Off. Previously, Mr. Jimenez served as Vice President, General Counsel and Corporate Secretary of Raytheon Company, a defense contractor, from January 2015 to April 2020 and, following Raytheon's merger with United Technologies Corporation, as Executive Vice President and General Counsel (April 2020 to December 2021) and Special Advisor to the Chairman and Chief Executive Officer (December 2021 to February 2022) of Raytheon Technologies Corporation, an aerospace and defense company. In prior public company positions, Mr. Jimenez served as General Counsel of Bunge Limited, ITT Corporation, and ITT spin-off Xylem Inc. In prior public service positions, Mr. Jimenez served as General Counsel of the Navy, Deputy General Counsel of the U.S. Department of Defense, Principal Deputy General Counsel of the Navy, Chief of Staff at the U.S. Department of Housing and Urban Development, and Deputy Chief of Staff and Acting General Counsel for former Florida Governor Jeb Bush. He was previously a litigation partner at Steel Hector & Davis LLP (now Squire Patton Boggs LLP). Mr. Jimenez serves on the boards of Huntington Ingalls Industries (NYSE: HII), where he serves on the compensation committee and the governance and policy committee; the Ann & Robert H. Lurie Children's Hospital of Chicago and Medical Center; and Equal Justice Works, where he serves as Chairman. He also serves on the advisory boards of the Columbia University Mailman School of Public Health and the Yale Law School Center for the Study of Corporate Law, as well as on the University of Miami President's Council.
Frank R. Jimenez自2022年2月起担任医疗器械制造和制药公司GE Healthcare的总法律顾问,并在通用电气公司分拆出TERM3后自2023年1月起担任公司秘书。自2020年4月至担任现职,Jimenez先生担任雷神技术公司执行副总裁兼总法律顾问(2020年4月至2021年12月)以及董事长兼首席执行官特别顾问(2021年12月至2022年2月)。自2015年1月至2020年4月与联合技术公司合并,担任雷神公司副总裁、总法律顾问和公司秘书。2012年7月至2015年1月,Jimenez先生担任农业综合企业和食品公司Bunge Limited的公司事务总法律顾问、秘书和董事总经理。此前,他曾担任ITT公司副总裁兼总法律顾问,并在ITT公司的衍生公司Xylem Inc.担任高级副总裁、总法律顾问和公司秘书。在此前的公共服务中,希门尼斯先生曾担任第21任海军总法律顾问、美国国防部副总法律顾问(法律顾问)、海军首席副总法律顾问、美国住房和城市发展部部长Mel Martinez的参谋长,以及佛罗里达州州长杰布·布什的副参谋长和代理总法律顾问。在进入政府部门服务之前,Jimenez先生是Steel Hector and Davis LLP(现为Squire Patton Boggs LLP)的诉讼合伙人。他的法律生涯始于加利福尼亚州帕萨迪纳市美国第九巡回上诉法院法官帕梅拉·安·赖默的内庭担任书记员。希门尼斯过去和现在的公民服务包括迈阿密大学、Equal Justice Works、Pro Bono Partnership、大西洋法律基金会、哥伦比亚大学梅尔曼公共卫生学院、耶鲁法学院基金、耶鲁法学院协会、耶鲁法学院公司法研究中心、PioneerLegal和迈阿密基督教学校的董事会成员。希门尼斯获得了迈阿密大学的学士学位和耶鲁大学法学院的法学博士学位。他还获得了宾夕法尼亚大学沃顿商学院金融和战略管理硕士学位和美国海军战争学院国家安全和战略研究硕士学位,重点是武装冲突法。希门尼斯获准在佛罗里达州、哥伦比亚特区、纽约州和美国最高法院任职。
Frank R. Jimenez,has served as General Counsel and Corporate Secretary since Spin-Off from GE. He served as the General Counsel of GE's healthcare business from February 2022 until the Spin-Off. Previously, Mr. Jimenez served as Vice President, General Counsel and Corporate Secretary of Raytheon Company, a defense contractor, from January 2015 to April 2020 and, following Raytheon's merger with United Technologies Corporation, as Executive Vice President and General Counsel (April 2020 to December 2021) and Special Advisor to the Chairman and Chief Executive Officer (December 2021 to February 2022) of Raytheon Technologies Corporation, an aerospace and defense company. In prior public company positions, Mr. Jimenez served as General Counsel of Bunge Limited, ITT Corporation, and ITT spin-off Xylem Inc. In prior public service positions, Mr. Jimenez served as General Counsel of the Navy, Deputy General Counsel of the U.S. Department of Defense, Principal Deputy General Counsel of the Navy, Chief of Staff at the U.S. Department of Housing and Urban Development, and Deputy Chief of Staff and Acting General Counsel for former Florida Governor Jeb Bush. He was previously a litigation partner at Steel Hector & Davis LLP (now Squire Patton Boggs LLP). Mr. Jimenez serves on the boards of Huntington Ingalls Industries (NYSE: HII), where he serves on the compensation committee and the governance and policy committee; the Ann & Robert H. Lurie Children's Hospital of Chicago and Medical Center; and Equal Justice Works, where he serves as Chairman. He also serves on the advisory boards of the Columbia University Mailman School of Public Health and the Yale Law School Center for the Study of Corporate Law, as well as on the University of Miami President's Council.